Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial. J Clin Oncol 2018; 36: 3126-3133.

Published: 22nd March 2019

Authors: Bardia A, Parton M, Kummel S, Estevez LG, Huang C-S, Cortes J et al.

Conclusion

Of 209 enrolled women, 32 per cent were gene signature (GS) negative. Pathological complete response was higher in the active arm in GS positive tumours (38 versus 17 per cent), but similarly poor in GS negative tumours.

Pubmed Link

Your comments

0 Comments